|1.||Williams, James W: 2 articles (04/2015 - 10/2014)|
|2.||Soldano, Stefano: 2 articles (05/2009 - 01/2009)|
|3.||Brizzolara, Renata: 2 articles (05/2009 - 01/2009)|
|4.||Sulli, Alberto: 2 articles (05/2009 - 01/2009)|
|5.||Montagna, Paola: 2 articles (05/2009 - 01/2009)|
|6.||Cutolo, Maurizio: 2 articles (05/2009 - 01/2009)|
|7.||Brouwers, J R B J: 2 articles (04/2005 - 09/2004)|
|8.||van Roon, E N: 2 articles (04/2005 - 09/2004)|
|9.||Yska, J P: 2 articles (04/2005 - 09/2004)|
|10.||Samardzic, T: 2 articles (08/2002 - 01/2001)|
04/01/2003 - "To analyse in vitro the possible anti-inflammatory effects exerted by A77 1726, on cultured macrophages, obtained from the synovial tissues of patients with rheumatoid arthritis (RA). "
08/15/1996 - "These results suggest that the immunomodulating agent A77 1726 (currently in clinical phase III studies for the treatment of rheumatoid arthritis) is a very good inhibitor of human dihydroorotate dehydrogenase."
09/07/2005 - "Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes."
09/01/2005 - "Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis."
04/01/2005 - "Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis."
10/01/2002 - "Both systemic and centrally administered A77 1726 significantly reduced mechanical allodynia across the time course of the study (P < .05). "
10/01/2002 - "This study was undertaken to determine whether the active metabolite of leflunomide (A77 1726), an anti-inflammatory and immunosuppressive agent, could attenuate persistent mechanical allodynia in a rodent L5 spinal nerve transection model. "
|4.||Type 1 Diabetes Mellitus (Autoimmune Diabetes)
01/01/2004 - "A77 1726 alone had no effect, but in the presence of IL-1beta or tumour necrosis factor-alpha it markedly enhanced the secretion of IL-1Ra in synovial fibroblasts and chondrocytes. "
01/01/2003 - "Human synoviocytes were stimulated with IL-1alpha or tumour necrosis factor alpha (TNF-alpha) in the presence of A77 1726. "
11/01/2000 - "Recent evidence suggests that the observed anti-inflammatory effects of A77 1726 may relate to its ability to suppress interleukin 1 and tumour necrosis factor alpha selectively over their inhibitors in T lymphocyte/monocyte contact activation. "
11/01/2008 - "A77 1726 dose-dependently reduces GCDCA-induced apoptosis and necrosis, but not menadione- or TNFalpha/ActD-induced apoptosis. "
04/01/2003 - "The effects of different doses of A77 1726 on intracytoplasmic expression and extracellular concentration of inflammatory cytokines (tumour necrosis factor alpha (TNFalpha), interleukin (IL) 1beta, IL6), as well as the influence on production and expression of intercellular adhesion molecule-1 (ICAM-1) and cyclo-oxygenase 2 (COX-2) by primary cultures of synovial macrophages from patients with RA, were evaluated by immunocytochemistry and western blot analysis. "
|3.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|5.||Insulin Receptor Substrate Proteins
|6.||Interleukin 1 Receptor Antagonist Protein (Anakinra)
|7.||Ribosomal Protein S6
|8.||Vitamin K 3 (Menadione)
|9.||Cytochrome P-450 CYP1A2 (CYP1A2)
|10.||Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
|1.||Transplantation (Transplant Recipients)